Previous close | 1,961.00 |
Open | 1,960.00 |
Bid | 1,939.00 x 0 |
Ask | 1,942.00 x 0 |
Day's range | 1,937.00 - 1,967.00 |
52-week range | 1,052.00 - 2,020.00 |
Volume | |
Avg. volume | 406,077 |
Market cap | 13.636B |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | 218.20 |
EPS (TTM) | 8.90 |
Earnings date | 14 Feb 2023 - 20 Feb 2023 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | 16 Jun 2016 |
1y target est | 21.29 |
WASHINGTON (Reuters) -Sen. Elizabeth Warren, an outspoken critic of corporate consolidation, wrote to the U.S. Federal Trade Commission to express concern about two pending pharmaceutical deals. In a letter dated Wednesday, Warren said that she was focused on Amgen's plan to buy Horizon Therapeutics, and addiction specialist Indivior's plan to buy Opiant for $145 million, which was announced in mid-November.
Investing can be hard but the potential fo an individual stock to pay off big time inspires us. But when you hold the...
Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...